{"podcast":{"title":"BioSpace","slug":"biospace-6696251","podcast_index_feed_id":6696251,"rss_url":"https://api.riverside.fm/hosting/3SxyDAXU.rss","website_url":"https://www.biospace.com/","image_url":"https://hosting-media.riverside.com/media/imports/podcasts/a2a52916-bfe1-4f2a-b9a3-9be5029ecbe4/39510587-1699400129885-1e919ae7cb2aa.jpg","author":"BioSpace","episode_count":247,"summary":"Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.","last_synced_at":"2026-07-15T16:19:04.105662+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251"},"episode":{"title":"Fibrosis, IPF and the search for better therapies","slug":"fibrosis-ipf-and-the-search-for-better-therapies","published_at":"2026-05-07T07:00:00+00:00","page_url":"https://stenobird.com/podcast/biospace-6696251/fibrosis-ipf-and-the-search-for-better-therapies","show_page_url":"https://stenobird.com/podcast/biospace-6696251","url":"https://api.riverside.com/hosting-analytics/media/3bb3ef6e9c30d3420c9158d73220f6f31ece48439f13eb7f09f0221bb66ee43d/eyJlcGlzb2RlSWQiOiJiMjcyNTkxNi0xOGY3LTRjZTctODMxYS0yNDdmZWQyNzU4Y2YiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjlmYjBlZWI4ZDlkYmZjYTFhYzY3N2M0L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTZfXzExLTUwLTM1Lm1wMyJ9.mp3","audio_url":"https://api.riverside.com/hosting-analytics/media/3bb3ef6e9c30d3420c9158d73220f6f31ece48439f13eb7f09f0221bb66ee43d/eyJlcGlzb2RlSWQiOiJiMjcyNTkxNi0xOGY3LTRjZTctODMxYS0yNDdmZWQyNzU4Y2YiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNjlmYjBlZWI4ZDlkYmZjYTFhYzY3N2M0L2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTZfXzExLTUwLTM1Lm1wMyJ9.mp3","summary":"In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer of Calluna Pharma. We dive into IPF and fibrosis challenges, unpacking treatment hurdles, emerging targets, unmet needs and expansion paths beyond the lung. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Georg Vo Beiske , CEO, Tribune Therapeutics Jonas Hallén , Co-Founder & CMO, Calluna Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.","meta_description":"In this episode of Denatured, you'll be hearing from Georg Vo Beiske, CEO of Tribune Therapeutics and Jonas Hallén, co-founder & Chief Medical Officer…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1080,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/fibrosis-ipf-and-the-search-for-better-therapies/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/biospace-6696251/fibrosis-ipf-and-the-search-for-better-therapies.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}